| Literature DB >> 31952137 |
Alejandro Martínez-Rodríguez1, Daniela Alejandra Loaiza-Martínez2, Javier Sánchez-Sánchez3,4, Pablo J Marcos-Pardo2, Soledad Prats1, Fernando Alacid5, Jacobo A Rubio-Arias6.
Abstract
Celiac disease (CD) is an immunological disorder that mainly affects the small intestine, generating an inflammatory process in response to the presence of gluten (a protein). Autoimmune diseases are part of a group of diseases that are difficult to diagnose without a specific protocol or consensus to detect them due to the number of symptoms and diseases with which it has a relationship. Therefore, the aim of this review was to analyze the diagnostic tools of CD used in middle-aged women, to compare the use and effectiveness of the different tools, and to propose a strategy for the use of the tools based on the results found in the literature. The present research followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. The search was conducted in the following databases: Scielo, PubMed, Web of Science, and Worldwide Science org. In the initial literature search, 2004 titles and relevant abstracts were found. Among them, 687 were duplicates, leaving 1130 articles. Based on the inclusion criteria, only 41 articles passed the selection process; 4 main types of analyses appear in the studies: blood tests, questionnaires, clinical history, and biopsy. It can be said that none of the analyses have a 100% reliability since most of them can present false negatives; therefore, the best way to diagnose celiac disease up to now is through a combination of different tests (Immunoglobulin A and small intestinal biopsy).Entities:
Keywords: diagnosis; diet; gluten; symptoms; women
Year: 2020 PMID: 31952137 PMCID: PMC7014319 DOI: 10.3390/ijerph17020539
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow diagram of the process of study selection.
Characterization of the articles.
| Study | H Index | Age | Amount | Analysis |
|---|---|---|---|---|
| Churruca et al. [ | 62 | 16 or + | 54 | Anthropometric measures, body composition, questionnaires, dietary assessment, serological testing, and intestinal biopsy |
| Stein et al. [ | 111 | 20–50 | 66 | Serological testing, tomography, and densitometry |
| Turner et al. [ | 57 | 51 ± 16 | 32 | Clinical history, anthropometric measures, densitometry, urine analysis, dietary intake, serological testing, and intestinal biopsy |
| Roos et al. [ | 13 | 20 or + | 16 | Interview and clinical history |
| Ehsani-Ardakani et al. [ | 18 | 32 ± 15 | 130 | Clinical history and serum analysis |
| Fiolkova et al. [ | 14 | NA | NA | Clinical history and analysis of literary sources |
| Rees [ | 45 | +18 | 198 | Clinical history and serum analysis |
| Peterson et al. [ | 27 | NA | NA | Physical examination, serological testing, intestinal biopsy, and response to a GFD (Gluten Free Diet) |
| Belen Zanchetta et al. [ | 61 | 18–49 | 53 | Serological testing and densitometry |
| Kocuvan Mijatov et al. [ | 7 | 23–76 | 40 | Clinical history, questionnaires, and dietary assessment |
| Santonicola et al. [ | 93 | +18 | 103 | Clinical history and questionnaires |
| Jacobsson et al. [ | 47 | 20 or + | 106 | Clinical history and questionnaires |
| Passananti et al. [ | 42 | 20–60 | 95 | Clinical history, serum analysis, and anthropometric measures |
| Fortunato et al. [ | 55 | 17–49 | 91 | Clinical history |
| Zanchetta et al. [ | 74 | 19–50 | 31 | Clinical history, serum analysis, and densitometry |
| Pinkerton et al. [ | 116 | 62 | 1 | Clinical history, serum analysis, and densitometry |
| Jacobsson et al. [ | 47 | 30–75 | 54 | Interview and clinical history |
| Singh et al. [ | 102 | NA | NA | Clinical history |
| Tursi et al. [ | 52 | 22–37 | 13 | Clinical history |
| Freeman [ | 82 | NA | NA | Clinical history and analysis of literary sources |
| Duerksen et al. [ | 29 | 20 or + | 376 | Clinical history, serum analysis, and densitometry |
| Bykova et al. [ | 11 | 18 or + | 217 | Clinical history, serum analysis, and biopsy |
| Dhalwani et al[ | 142 | 25–29 | 2,426,225 | Clinical history and analysis of literary sources |
| Sóñora et al. [ | 37 | 18–60 (36) | 50 | Clinical history and serum analysis |
| Sharshiner et al. [ | 30 | 30 ± 4.5 | 232 | Clinical history and serum analysis |
| Ciacci et al. [ | 42 | 21–45 | 111 | Clinical history, anthropometric measures, serological testing, and genetic analysis |
| Choi et al. [ | 18 | 25–39 | 191 | Serological testing with hormones tests and intestinal biopsy |
| Moleski et al. [ | 24 | +18 | 970 | Clinical history, serological testing, intestinal biopsy, and questionnaire |
| Kavuncu et al. [ | 41 | 62.75 ± 8.58 | 192 | Clinical history, body mass index, serological testing, biochemical analyses, and densitometry. |
| Fabbri et al. [ | 129 | 26 | 1 | Clinical history, brain tomography, serological, biochemical analyses, and cardiovascular analysis. |
| Ludvigsson et al. [ | 212 | Any age | 107,124 | Clinical history and biopsy |
| Sonora et al. [ | 37 | 29–47 | 10 | Clinical history, serological tests, and immunostaining of placental tissue sections |
| Sultan et al. [ | 234 | 15–44 | 276,586 | Clinical history |
| Stephansson et al. [ | 72 | +18 | 66,089 | Clinical history and biopsy |
| Martinelli et al. [ | 40 | 15–49 | 248 | Clinical history, serum analysis, biopsy, and questionnaire |
| Tejera-Alhambra et al. [ | 85 | 29–44 | 79 | Serum analysis |
| Hasan [ | – | 24–46 | 50 | Clinical history and serum analysis |
| Mohammadibakhsh et al. [ | 12 | NA | NA | Clinical history, serum analysis, biopsy, questionnaire, and analysis of literary sources |
| Lasa et al. [ | 25 | NA | NA | Clinical history, serum analysis, biopsy, questionnaire, and analysis of literary sources |
| Ludvigsson et al. [ | 114 | 16 or + | 109,327 | Clinical history, serum analysis, biopsy, and analysis of literary sources |
| Ludvigsson et al. [ | 112 | NA | 173,608 | Clinical history, serum analysis, biopsy, and analysis of literary sources |
Diagnostic tests (invasive)/description of the different analyses and tests performed on patients and for what they are used.
| Acronym | Name | Instrument for | Objective | Population | Reference Values | Characteristics |
|---|---|---|---|---|---|---|
| - | Intestinal biopsy | Clinical diagnosis of diseases like celiac disease | Observe the tissue | People with an IgA *1 elevated and symptomatic (celiac) | Healthy for celiac disease: without the presence of IgA | It is a surgical procedure by which a sample is extracted from tissue to be able to rule out the presence of different pathologies |
| - | Endoscopy | Observe and obtain tissue samples | Observe and obtain tissue samples | Population at risk or symptomatic | Normal cells | “It is a procedure that allows the doctor to see the inside of your body”. [ |
| IgA | Immuno-globulin A | Helps clinical diagnosis of diseases like celiac disease | Measure the amount of immunoglobulin A in blood | Symptomatic people (celiac) | Healthy: 70–350 mg *5/dL *2 (0.70–3.50 g *3/L*4) | It is measured in blood serum; it is done through the test ELISA *5 and carries few risks. |
| tTg | Transglutaminase anti-inflammatory | Helps clinical diagnosis of diseases like celiac disease | Measure the amount of anti-inflammatory transglutaminase in blood | Symptomatic people (celiac) | They are not specified as they depend on the laboratory and population. | |
| IgG | Immunoglobulin G | Helps clinical diagnosis of diseases like celiac disease | Measure the amount of immunoglobulin G | Symptomatic people (celiac) | Healthy: 700–1,700 mg/dL (7.0–17.0 g/L) | |
| IgM | Immunoglobulin M | Helps clinical diagnosis of diseases like celiac disease | Measure the amount of immunoglobulin M | Symptomatic people (celiac) | Will depend on the laboratory that performs the test | |
| - | Metabolomics | Helps clinical diagnosis of diseases like celiac disease | Measure and study of small molecules | Symptomatic people (celiac) | Presence or absence of certain molecules and proteins for example P-cresol sulfate. | “Is the systematic study of the small molecular metabolites in a cell, tissue, biofluid, or cell culture media that are the tangible result of cellular processes or responses to an environmental stress.” [ |
| IRMA *9 | Immuno-radiometric assay | Clinical diagnosis of diseases like celiac disease | Measure the amount of antigen and labeled antibodies | Symptomatic people | Presence or absence of antigens. | Using florescence, they are labeled with radioactive isotopes of the antibodies in order to find the antigen that is causing the pathology. |
| - | Genetic Study | Clinical diagnosis of diseases with genetic implication, like celiac disease | Observe the chromosomes | Symptomatic people | Status of chromosomes, absence of mutations. | Uses blood cells to generate cell growth and to be able to study multiple cells during metaphase and, with this, being able to observe the karyotype of each individual and study their DNA *9. |
*1 Immunoglobulin A, *2 Deciliters, *3 Grams, *4 Litter, *5 Enzyme-Linked Immuno Sorbent Assay Milligrams, *6 Transglutaminase anti-inflammatory, *7 Immunoglobulin G, *8 Immunoglobulin M, *9 Immunoradiometric assay.
Diagnostic tests (noninvasive)/description of the different analyses and tests performed on patients and for what they are used.
| Acronym | Name | Instrument for | Objective | Population | Reference Values | Characteristics |
|---|---|---|---|---|---|---|
| CSI *1 | Celiac Symptom Index | Monitoring of symptoms | It is made up of sixteen items, 11 of which evaluate “specific symptoms “and 5 evaluate “general health”. [ | Celiac | More than 45 means | It is a questionnaire-type test. |
| - | Food Frequency questionnaire | Evaluation of the eating habits | Measure the food groups consumed and its frequency | All the population | WHO values | It is a type of test where the frequency with which the individual consumes certain foods is evaluated. |
| MDS *2 | Mediterranean Diet Score | Evaluation of the eating habits compared with the Mediterranean Diet. | Compares the patient’s intake with that recommended in the Mediterranean diet | All the population | The values are between 0 and 55: more points better habits. | It is a questionnaire-type test. |
*1 Celiac Symptom Index. *2 Mediterranean Diet Score.
Figure 2Flow diagram with the suggested steps to diagnose celiac disease. IgA: Immuno-globulin A, IgG: Immuno-globulin G, IgM: Immuno-globulin G, tTg: Transglutaminase anti-inflammatory. * In case the patient has an evident improvement with the treatment (gluten-free diet), it will be continued; otherwise, the presence of other pathologies should be studied.